Korro Bio (KRRO) Stock Price

Korro Bio Price

NASDAQ·CLOSED
10.58
​
Market closed

Revenue at Korro Bio has contracted by 22.3% per year over the past 6 years to 6.39 M USD. Korro Bio's net margin stands at -1,834.5%, down from -64.8% several years earlier. Analysts set a median price target of 22.00 USD, implying 107.9% above the current price. Of 18 analysts, 16 rate the stock a buy — an overall Buy consensus.

Korro Bio stock price

Access this data via the Eulerpool API

Korro Bio business model & stock analysis

Korro Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2019-10-03. Korro Bio, Inc. is a biopharmaceutical company. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. OPERA co-opts the cell’s natural process with its synthetic oligo and catalyzes a single base change to modify protein sequence and function without the need to permanently modify one’s genome. The firm's focus areas include the liver and central nervous system (CNS).

Frequently asked questions about Korro Bio

Analysts currently set an average price target of 20.00 USD for the Korro Bio stock (median: 22.00 USD), implying +89.0 % versus the latest price. The consensus is based on 18 analyst ratings.

18 analysts currently rate the Korro Bio stock: 16 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Korro Bio to generate revenue of 333,333.00 USD and earnings per share of -5.33 USD.

Converted at the current exchange rate, the Korro Bio share trades at 9.44 EUR (10.58 USD).

The Korro Bio share (KRRO) is listed on 1 stock exchanges, including: NASDAQ (FREQ).

The expected revenue of Korro Bio is 333,333.00 USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Korro Bio is -50.06 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Korro Bio is currently -1.99. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Korro Bio stock.

The price-to-sales ratio (P/S) of Korro Bio is currently 298.21. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Korro Bio stock.

The Eulerpool Quality Score for Korro Bio is 3/10.

The ISIN of Korro Bio is US5009461089. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Korro Bio is KRRO. The ticker symbol is used to trade Korro Bio shares on the stock exchange.

Fair ValueTerminal
10.16 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
110,206.90 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website korrobio.com
Currency
USD
Initial public offering
Oct 3, 2019
ISIN
US5009461089
Cusip
500946108
Market capitalization
99.66 M USDMicro Cap
52-Week Range
PEG
0.43
P/E ratio
P/Ee 2026
-1.99
P/Ee 2027
-2.16
P/Ee 2028
-2.54
P/Ee 2029
-2.34
P/Ee 2030
-2.19
P/Se
298.21
EV/EBIT
—
P/B Ratio
1.94
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-123.53 %
Last updated Oct 9, 2026, 12:02 PM

Korro Bio Peer Group

Korro Bio Ticker

NASDAQ · FREQ

Korro Bio FIGI

KRRO:US · BBG00GFMTC38KRRO:UA · BBG00Q6Q1DG1KRRO:UC · BBG00Q6Q1DH0KRRO:UN · BBG00Q6Q1DK6KRRO:UP · BBG00Q6Q1DL5KRRO:UB · BBG00Q6Q1DN3KRRO:UM · BBG00Q6Q1DQ0KRRO:UX · BBG00Q6Q1DR9KRRO:UR · BBG00Q6Q1DS8KRRO:UD · BBG00Q6Q1DX2KRRO:UF · BBG00Q6Q1F03KRRO:VY · BBG00Q6Q1F12

All fundamentals and in-depth analysis of Korro Bio

Our stock analysis for Korro Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Korro Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.